BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BridgeBio Oncology Therapeutics, Inc. stock (BBOT) is currently trading at $8.72. Analyst consensus price target for BBOT is $24.20. WallStSmart rates BBOT as Sell.
- BBOT PE ratio analysis and historical PE chart
- BBOT PS ratio (Price-to-Sales) history and trend
- BBOT intrinsic value — DCF, Graham Number, EPV models
- BBOT stock price prediction 2025 2026 2027 2028 2029 2030
- BBOT fair value vs current price
- BBOT insider transactions and insider buying
- Is BBOT undervalued or overvalued?
- BridgeBio Oncology Therapeutics, Inc. financial analysis — revenue, earnings, cash flow
- BBOT Piotroski F-Score and Altman Z-Score
- BBOT analyst price target and Smart Rating
BridgeBio Oncology Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Significant fundamental concerns warrant caution or avoidance.
BridgeBio Oncology Therapeutics, Inc. (BBOT) Key Strengths (2)
Trading at 1.76x book value, attractively priced
51.02% held by institutions, strong professional interest
Supporting Valuation Data
BridgeBio Oncology Therapeutics, Inc. (BBOT) Areas to Watch (1)
Small-cap company with higher risk but more growth potential
BridgeBio Oncology Therapeutics, Inc. (BBOT) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 2 register as strengths (avg 8.0/10) while 1 fall into concern territory (avg 5.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.76) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BBOT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Loading insider activity...
About BridgeBio Oncology Therapeutics, Inc.(BBOT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.